Abcellera Biologics is trading $12.20 (+4.18%) amid supportive biotech and broader market conditions.
- Biotech rose 2.10%, alongside gains in major U.S. indices.
- No new company-specific announcement explaining the October 21 move surfaced in the search. AbCellera’s previously announced ABCL635 data presentation is scheduled for October 22, not a new announcement today.
- The presentation and prior Phase 2 results may keep attention on the company, but do not establish a direct cause for today’s rise.